NIOX Group
{{Use dmy dates|date=April 2022}}
{{Orphan|date=April 2022}}
{{Infobox company
| name = NIOX Group plc
| logo = NIOX Group Logo.jpg
| type = Public limited company
| traded_as = {{lse|NIOX}}
| industry = Medical Devices
| foundation = {{Start date and age |2006 }}{{cite web|url=http://shares.telegraph.co.uk/fundamentals/?epic=CIR|title=Fundamentals for Circassia Pharmaceuticals Ord 0.08p|publisher=The Telegraph|accessdate=23 August 2014}}
| founders = Steve Harris and Charles Swingland{{cite web|url=http://shares.telegraph.co.uk/fundamentals/?epic=CIR|title=Fundamentals for Circassia Pharmaceuticals Ord 0.08p|publisher=The Telegraph|accessdate=23 August 2014}}
| location_city = Oxford
|location_country = United Kingdom
| key_people = Ian Johnson (Executive Chairman)
Michael Roller (CFO)
Jonathan Emms (COO)
| products = NIOX VERO, FeNO by NIOX
| revenue = {{increase}} £41.8 million (2024){{cite web |url=https://otp.tools.investis.com/clients/uk/circassia/rns/regulatory-story.aspx?cid=797&newsid=1923805|title=Final Results 2024|publisher=NIOX Group plc|access-date=1 April 2025}}
|operating_income={{increase}} £7.7 million (2024)
|net_income={{decrease}} £3.4 million (2024)
| homepage = {{URL |http://www.niox.com/ }}
}}
NIOX Group is a British medical device manufacturing company focussed on products for treating people suffering from respiratory diseases. It produces its NIOX (Nitric Oxide) range of FeNO (Fractional Exhaled Nitric Oxide) devices to help diagnose and manage asthma.{{Cite web|title=Company|url=https://www.circassia.com/|url-status=live|access-date=29 March 2021|website=Circassia|language=en-US|archive-url=https://web.archive.org/web/20040324190950/http://circassia.com:80/ |archive-date=2004-03-24 }}
The company is a provider of point-of-care FeNO (Fractional Exhaled Nitric Oxide) measurement and monitoring. The company is listed on the London Stock Exchange.
History
The company was founded by Steve Harris and Charles Swingland as Circassia Group in 2006.{{cite web|url=http://shares.telegraph.co.uk/fundamentals/?epic=CIR|title=Fundamentals for Circassia Pharmaceuticals Ord 0.08p|publisher=The Telegraph|accessdate=23 August 2014}} It was the subject of an initial public offering in March 2014.{{cite web|url=https://www.wsj.com/news/articles/SB10001424052702303730804579436630697203704|title=Circassia IPO Fuels Optimism on European Biotech|publisher=Wall street Journal|date=13 March 2014|accessdate=23 August 2014}}
In December 2019, Steve Harris announced that he was resigning as CEO of the company. Ian Johnson took over as Executive Chairman of the company, Michael Roller replaced Julien Cotta as the Chief Financial Officer, and Jonathan Emms, who was appointed to the company in September 2019, became the Chief Operating Officer.{{Cite web|url=https://www.sharecast.com/news/aim-bulletin/circassia-appoints-jonathan-emms-to-new-coo-role--6929026.html|title=Circassia appoints Jonathan Emms to new COO role|date=12 August 2019|publisher=Sharecast|access-date=29 March 2021}}
The company also announced its withdrawal from the COPD (chronic obstructive pulmonary disease) business in April 2020, with a proposed transfer of assets to, and termination of agreement with, AstraZeneca for consideration to be set off against debt and accrued interest.{{Cite web|title=Circassia pulls plug on AZ agreement|url=http://www.pharmatimes.com/news/circassia_pulls_plug_on_az_agreement_1338010|date=9 April 2020|publisher=PharmaTimes|access-date=29 March 2021}}
In 2022 the company changed its name from Circassia Group plc to NIOX Group plc.{{Cite web|title=Circassia Group plc renames to NIOX Group plc |url=https://www.londonstockexchange.com/news-article/NIOX/result-of-general-meeting-and-change-of-name/15610256|date=1 September 2022|publisher=London Stock Exchange|access-date=23 November 2023}}
Operations
NIOX Group has direct offices in the United Kingdom, United States, Germany, Sweden and China. The company also operates through a distribution model, working with partner companies in order make NIOX available throughout the globe.{{Cite web|title=Locations|url=https://www.investors.niox.com/contacts/locations/|access-date=2023-11-23|website=NIOX|language=en-US}}
Products
NIOX (Nitric Oxide) is a FeNO testing device. Using visual aids and sounds, NIOX provides an easy to use test experience to help patients perform FeNO (Fractional Exhaled Nitric Oxide) tests.{{Cite web|title=FeNO by NIOX {{!}} Enhanced Asthma Management {{!}} United States|url=https://www.niox.com/en-us/|access-date=2021-03-29|website=NIOX.com|language=EN}}
FeNO aids healthcare professionals with the diagnosis and management of asthma.
References
{{Reflist}}
External links
- [http://www.investors.niox.com/ Official investor website]
- [https://niox.com/ NIOX product website]
{{Authority control}}